<SEC-DOCUMENT>0001193125-24-276918.txt : 20241212
<SEC-HEADER>0001193125-24-276918.hdr.sgml : 20241212
<ACCEPTANCE-DATETIME>20241212153326
ACCESSION NUMBER:		0001193125-24-276918
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20241212
FILED AS OF DATE:		20241212
DATE AS OF CHANGE:		20241212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		241544635

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d891896d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as December&nbsp;12, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d891896dex991.htm">Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: December 12, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d891896dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g891896g30z01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Reports Promising New Data in Head and Neck Cancer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>at ESMO Immuno-Oncology 2024 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Data shows strong overall survival, progression-free survival, and durability from novel combination of efti
in combination with pembrolizumab in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> head and neck cancer patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> CPS &lt;1</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Positively, median overall survival (OS) has not yet been reached and the
<FONT STYLE="white-space:nowrap">12-month</FONT> OS rate is 67%, both well above historical controls</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Complete response rate increases to 12.9% and 16.1%, according to RECIST 1.1 and iRECIST, respectively</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Treatment continues to be well tolerated </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 12</B><B></B><B>&nbsp;December </B><B>2024 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or
&#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces positive clinical results from Cohort B of the <FONT
STYLE="white-space:nowrap">TACTI-003</FONT> <FONT STYLE="white-space:nowrap">(KEYNOTE-C34)</FONT> Phase IIb trial. This study evaluates eftilagimod alpha (efti) in combination with MSD&#146;s (Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA) <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) in first line recurrent/metastatic head and neck squamous cell carcinoma
(1L HNSCC) patients with negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The new promising data presented by Martin Forster, M.D.,
Ph.D., at the ESMO Immuno-Oncology (IO) Annual Congress 2024 includes strong overall survival, progression-free survival, and durability. This adds to the high response rates and favourable safety data previously reported on 12&nbsp;July 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof. Martin Forster of the UCL Cancer Institute and University College London Hospital NHS Foundation Trust, London, UK, and <FONT
STYLE="white-space:nowrap">TACTI-003</FONT> Investigator, stated</B>, &#147;The new survival and durability data, coupled with increasing complete responses, build on the strong response rates already established with this novel IO combination in
head and neck squamous cell cancers with <FONT STYLE="white-space:nowrap">PD-L1</FONT> CPS &lt;1. This <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> disease places a high burden on patients who
unfortunately have very limited treatment options that all include chemotherapy. Collectively, these impressive results build on the potential promise of efti to improve patient outcomes and expand populations that respond to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1.&#148;</FONT></FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Data as of the 31&nbsp;October 2024 <FONT STYLE="white-space:nowrap">cut-off</FONT> date in evaluable 1L HNSCC patients (N=31) whose tumours express <FONT
STYLE="white-space:nowrap">PD-L1</FONT> below 1 (Combined Positive Score [CPS] &lt;1) and who typically do not respond well to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy alone shows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Positively, median overall survival (OS) has not yet been reached and the
<FONT STYLE="white-space:nowrap">12-month</FONT> OS rate is 67% </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Promising progression-free survival (PFS) of 5.8 months </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strong durability with interim median duration of response (DOR) of 9.3 months </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">High 35.5% objective response rate (ORR) and 58.1% disease control rate (DCR), as reported on 12&nbsp;July
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Complete response rate increases to 12.9% and 16.1%, according to RECIST 1.1 and iRECIST, respectively<SUP
STYLE="font-size:75%; vertical-align:top">1</SUP> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efti in combination with pembrolizumab continues to be well-tolerated with no new safety signals
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This data compares favourably to historical results from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy alone in 1L HNSCC patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> CPS &lt;1 including a <FONT STYLE="white-space:nowrap">7.9-month</FONT>
median OS, <FONT STYLE="white-space:nowrap">12-month</FONT> OS rate of 39%, <FONT STYLE="white-space:nowrap">2.1-month</FONT> median PFS, <FONT STYLE="white-space:nowrap">2.6-month</FONT> median DOR, 5.4% ORR and 32.4% DCR with no complete responses<SUP
STYLE="font-size:75%; vertical-align:top"><FONT STYLE="white-space:nowrap">2-3</FONT></SUP>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g891896g30z01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Marc Voigt, CEO of Immutep, noted, </B>&#147;Despite the significant progress of cancer immunotherapy over the past
decade and the positive change in the therapeutic landscape it has brought to bear, head and neck cancer patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression of less than one continue to have limited treatment options that all
include chemotherapy. We believe this data is an encouraging step in the right direction towards potentially bringing a new approach to this underserved population, representing up to 20% of patients with this difficult disease.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Next Steps </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients with
<FONT STYLE="white-space:nowrap">PD-L1</FONT> CPS &lt;1 is an underserved patient population with limited treatment options. Immutep will continue to follow the maturing data from <FONT STYLE="white-space:nowrap">TACTI-003</FONT> and engage with
regulatory authorities regarding potential paths forward. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ESMO IO poster is available on the&nbsp;Posters&nbsp;&amp; Publications&nbsp;section of
Immutep&#146;s website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC,
a subsidiary of Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune
disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio
harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information,
please visit <U>www.immutep.com</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Complete response rate was 9.6%, according to RECIST 1.1 and iRECIST, respectively, at earlier <FONT
STYLE="white-space:nowrap">cut-off</FONT> date as previously reported on 12&nbsp;July 2024 </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Burtness, B. et al. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous
Cell Carcinoma in <FONT STYLE="white-space:nowrap">KEYNOTE-048:</FONT> Subgroup Analysis by Programmed Death <FONT STYLE="white-space:nowrap">Ligand-1</FONT> Combined Positive Score. Journal of Clinical Oncology 2022 40:21, 2321-2332. Note, the 5.4%
ORR and 32.4% DCR are calculated from the 37 evaluable patients with CPS &lt;1. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>3.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Burtness B. et al. Abstract <FONT STYLE="white-space:nowrap">LB-258:</FONT> Efficacy of first-line (1L)
pembrolizumab by <FONT STYLE="white-space:nowrap">PD-L1</FONT> combined positive score &lt;1, <FONT STYLE="white-space:nowrap">1-19,</FONT> and </I>&#8805;<I></I><I>20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma
(HNSCC): <FONT STYLE="white-space:nowrap">KEYNOTE-048</FONT> subgroup analysis. Cancer Res 15&nbsp;August 2020; 80 (16_Supplement): LB&#150;258.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://doi.org/10.1158/1538-7445.AM2020-LB-258</FONT></FONT> </I></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Sodali&nbsp;&amp; Co </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>catherine.strong@sodali.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g891896g30z01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g891896g30z01.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MV&AQQO>RE!(V% &30!H(X= Z-N4@$$=Q0 ^@ H * "@ H * "@ H * "@ H
M#TH :3CKQ^- #J "@ H * "@ H J:E&\NG7$4>=[1L%QZXJ9(F:]T\^T.^,>
MHVT5UE[521L;D1GUK%:,\VE.TM3=\0:GI]]:"T@N8_/)&)!P%QZFJDSIJS7*
M5_!$;+?7I#!D"@;E^Z3GM51,\*FFV=LO2M#OO<6@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MHO8#U+2;]-4TNWO8QA9D#8]#W%%QEW'M19,6@8H&**!!0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M<:H/^)1>_P#7%_Y&MY?"=]5_NWZ'.^!.(;SZI_(UG2V.7"NZ.3C/D_$DESM
MOR<GW8ULSN9ZI?\ &G7/_7-OY&D(\S^&W_(R3?\ 7HW_ *&M $7Q"&/%'/'[
ME: /5("#!&>HP.?PH X/XFK(8=,8 [,N#['Y2/Y&@#,T+P[KFHZ5#<V.L^3
M2Q6,3.-AS[4 7+CP#KUWM^T:M%-MSM\R1VQGKU% &EXCL9--^'@LYF#O%L5F
M'0_-]* -#P#QX1MO]Y__ $(T 9/Q,DC6RT]./,,C,!Z# S0!L^!%9?"-IN!&
M2Y&?3<<4 =)0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 <EXRM+F[^R?9X))2N_=L7..E9S1RXF-[%_5+>:3PJ;=(V:7RD&
MT#GC&:J>Q=2/N%/P=:7%I#=?:(9(BS#&]2,U%-$X>'*1>,;*ZNWM#;P22[0V
M=BDXZ45$&(A<W=%C>'1[6.12C+& 0>U:QV-*2]TYV&QNQXU-R;:00>82)-O&
M-I[UBE[Y@H?O$Q_C"RNKNXMC;6\DH56!V)G'-%0*T+S.BTE&ATFT1U*LL2@A
MNHXJX;'3"-DD<B^G7G_"7^?]EE\K[2&WA>,;AS6;^,XY0_>W_K<Z_45:32KR
M-%+.8G  ZDX-;2^$ZZL;TVO(PO!MI<VD5W]HMWA+%2H=<9X-9TMC##4^5&)X
MP\+7QU0ZKIL;2AF#,D?WD8<[AZ\UL=C*;>(O&#VC6S6,S J4+&T8DYXI"+?@
M'1]0L=:FN;NSF@A,#*#(NW)+ ]#SVH N>//#5UJ,L6H641ED1-DD:\DCKP*
M,FWUWQBMK':16,^4 &6MSNQ[DT =OKFBIK^B?9IODGP'1C_ ^* //[6+Q7X5
MF>*WMIFC8Y.R(RQM[\<B@#1C\0>,[V:-4L98TW#<5MB!C//+4 =#X\S_ ,(E
M/D8.^//_ 'T* .*T35/$^FZ9$+"UDGLFSMQ"74'//(&10 Y='\1>*]4634(I
M8DZ-)+&8PJ_[(- 'J=E:1V-G%:PC$<2A10!8H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MJ@],F@"1KR",R;GQY6-P.1UZ?6@#!\>'/A*?G^-#_P"/4 +X!_Y%&V_WG_\
M0C0!TU !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@!*8:A0&H4!J% :A0&H4!J% :A0&H4
M!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4
M!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4
M!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4
M!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4
M!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H4!J% :A0&H<
M4!J% :G(#QU$<#[#)TS]X5ASG%]:0[_A.(O^?*3_ +Z%'.'UI!_PG$7_ #Y2
M?]]"CG#ZT@_X3B+_ )\I/^^A1SA]:0?\)Q%_SY2?]]"CG#ZT@_X3B+_GRD_[
MZ%'.'UI!_P )Q%_SY2?]]"CG#ZT@_P"$XB_Y\I/^^A1SA]:0?\)Q%_SY2?\
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M5)Q;LH?G!8>M/G#ZTCD&L;94R(NWJ:S,.5=B+[)!_P \A0'*NP?9(/\ GD*
MY5V#[)!_SR% <J[!]D@_YY"@.5=@^R0?\\A0'*NP?9(/^>0H#E78/LD'_/(4
M!RKL'V2#_GD* Y5V#[)!_P \A0'*NP?9(/\ GD* Y5V#[)!_SR% <J[!]D@_
MYY"@.5=@^R0?\\A0'*NP?9(/^>0H#E78/LD'_/(4!RKL'V2#_GD* Y5V#[)!
M_P \A0'*NP?9(/\ GD* Y5V#[)!_SR% <J[!]D@_YY"@.5=@^R0?\\A0'*NP
M?9(/^>0H#E78/LD'_/(4!RKL'V2#_GD* Y5V#[)!_P \A0'*NP?9(/\ GD*
MY5V#[)!_SR% <J[!]D@_YY"@.5=@^R0?\\A0'*NP?9(/^>0H#E78/LD'_/(4
M!RKL'V2#_GD* Y5V#[)!_P \A0'*NP?9(/\ GD* Y5V#[)!_SR% <J[!]D@_
MYY"@.5=@^R0?\\A0'*NP?9(/^>0H#E78/LD'_/(4!RKL'V2#_GD* Y5V#[)!
M_P \A0'*NP?9(/\ GD* Y5V#[)!_SR% <J[!]D@_YY"@.5=@^R0?\\A0'*NP
M?9(/^>0H#E78/LD'_/(4!RKL'V2#_GD* Y5V#[)!_P \A0'*NP?9(/\ GD*
MY5V#[)!_SR% <J[!]D@_YY"@.5=@^R0?\\A0'*NP?9(/^>0H#E78/LD'_/(4
M!RKL'V2#_GD* Y5V#[)!_P \A0'*NP?9(/\ GD* Y5V#[)!_SR% <J[!]D@_
MYY"@.5=@^R0?\\A0'*NP?9(/^>0H#E78/LD'_/(4!RKL'V2#_GD* Y5V#[)!
M_P \A0'*NP?9(/\ GD* Y5V#[)!_SR% <J[!]D@_YY"@.5=@^R0?\\A0'*NP
M?9(/^>0H#E78/LD'_/(4!RKL'V2#_GD* Y5V#[)!_P \A0'*NP?9(/\ GD*
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9/8D4!RKL=)IMM$NGPJJX 'J?6F'*NQ__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
